Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

JS, Smolen; M, Schöls; J, Braun; M, Dougados; O, FitzGerald; DD, Gladman; A, Kavanaugh; R, Landewé; P, Mease; J, Sieper; T, Stamm; M, Wit; D, Aletaha; X, Baraliakos; N, Betteridge; FVD, Bosch; LC, Coates; P, Emery; LS, Gensler; L, Gossec; P, Helliwell; M, Jongkees; TK, Kvien; RD, Inman; IB, McInnes; M, Maccarone; PM, Machado; A, Molto; A, Ogdie; D, Poddubnyy; C, Ritchlin; M, Rudwaleit; A, Tanew; B, Thio; D, Veale; K, Vlam; der Heijde D, van

doi:10.1136/annrheumdis-2017-211734

Public

Treating axial spondyloarthritis and peripheral spondyloarthritis, especially psoriatic arthritis, to target: 2017 update of recommendations by an international task force.

Shared by NobleBlocks on Jul 6, 2017 • 12:00 AM UTC

Authors:

Smolen JS

Schöls M

Braun J

Abstract

Therapeutic targets have been defined for axial and peripheral spondyloarthritis (SpA) in 2012, but the evidence for these recommendations was only of indirect nature. These recommendations were re-evaluated in light of new insights. Based on the results of a systematic literature review and expert ...

Subject

Treatment

Ankylosing spondylitis

Psoriatic Arthritis

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!